This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/drugbank/drug/DB05297/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05297/identifier/wikipedia/
n13http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB05297/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05297/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05297
rdf:type
n3:Drug
n3:description
A combination of DHA (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.
n3:dosage
n11:271B4088-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Bradley MO, Swindell CS, Anthony FH, Witman PA, Devanesan P, Webb NL, Baker SD, Wolff AC, Donehower RC: Tumor targeting by conjugation of DHA to paclitaxel. J Control Release. 2001 Jul 6;74(1-3):233-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11489499
n3:group
investigational
n3:indication
Investigated for use/treatment in breast cancer, colorectal cancer, gastric cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, and skin cancer.
owl:sameAs
n13:DB05297
dcterms:title
DHA-paclitaxel
adms:identifier
n6:5293670 n7:DHA-paclitaxel n8:DB05297 n9:6918473
n3:mechanismOfAction
A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel. Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer.
n3:IUPAC-Name
n4:271B408D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4093-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4092-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B408F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4090-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4091-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B408B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B408C-363D-11E5-9242-09173F13E4C5 n4:271B4089-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B408A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4099-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B409A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4094-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4095-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4097-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4096-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4098-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B409F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B40A1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B40A2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B409E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B409D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B40A0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B408E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B409B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B409C-363D-11E5-9242-09173F13E4C5